Welcome to our dedicated page for Evolus news (Ticker: $EOLS), a resource for investors and traders seeking the latest updates and insights on Evolus stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Evolus's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Evolus's position in the market.
Evolus has announced positive topline results from a U.S. pivotal study for its dermal fillers, Evolysse™ Lift and Smooth. Presented at the 2024 SCALE Meeting, the study showed that both products met primary and secondary endpoints, demonstrating superiority over Restylane-L in improving nasolabial fold severity at multiple time points. The safety profiles of the products were similar to Restylane-L with no serious adverse events. Evolus plans to submit Premarket Approval applications to the FDA within the next 90 days, potentially expanding their market by 78%, complementing their neurotoxin Jeuveau®.
Evolus celebrates the fifth anniversary of its flagship product, Jeuveau®, at the Women's Wear Daily (WWD) Beauty CEO Summit, where CEO David Moatazedi speaks.
Jeuveau® has been the fastest-growing aesthetic neurotoxin in the U.S. over the last three years, emphasizing the company's market impact. Evolus aims to redefine beauty through its performance beauty approach, focusing on younger demographics. The summit highlights Evolus' role in driving growth and innovation in global beauty.
Moatazedi reflects on Evolus' progress, evolving from a single-product company to a multi-product innovator in the beauty aesthetics space.
Evolus, Inc. reported granting stock options and restricted stock units to 14 new non-executive employees under the 2023 Inducement Incentive Plan. The awards have a vesting commencement date of May 7, 2024, with stock options priced at $13.42 per share and a 10-year term. RSUs vest annually over 4 years. The grants are compliant with Nasdaq Listing Rule 5635(c)(4).
Evolus, Inc. announced that Sandra Beaver, the Chief Financial Officer, has been honored as the Public Company CFO of the Year by the Orange County Business Journal. Since joining in 2022, she has significantly contributed to the company's growth and success. Sandra supported the licensing agreements expanding the product portfolio by adding late-stage dermal fillers in the U.S. and European markets, increasing the addressable market by 78% to $6 billion. She also led the geographic expansion to Austria, Germany, and Italy, guiding the company to financial success and strategic decision-making.
Evolus, Inc. (NASDAQ: EOLS) reported Q1 2024 net revenue of $59.3 million, a 42% increase from Q1 2023. They aim for non-GAAP profitability in Q4 2024 and full year 2025. The company completed U.S. clinical trials for Evolysse® Lift and Smooth fillers, with FDA submission expected soon. Evolus reaffirmed full-year 2024 net revenue guidance of $255 million to $265 million, on track to achieve total net revenue goal of $700 million by 2028.